Ki67 antibody and cell cycle reagents: reading proliferation without over-reading it

Choosing and reading a Ki-67 antibody marker

1. Decide whether you need cycling or division. Markers of the cycling state identify cells that are not quiescent. Measuring division requires incorporating a label over a defined window, which is a different experiment with a different reagent and a denaturation step.
2. Match the marker to the phase you care about. Licensing factors, phase specific cyclins and mitotic kinases each peak at different points. A marker chosen without regard to phase gives a number that mixes populations and cannot be compared across conditions that shift the distribution.
3. Fix fixation and retrieval per reagent. Nuclear proliferation markers are sensitive to fixation time and retrieval conditions, and a weak stain is far more often a retrieval problem than a reagent problem. Optimise on a tissue known to be proliferating.
4. Score consistently and say how. Percentage of positive nuclei, intensity thresholds and how partially stained nuclei are treated all change the number. Fix the scoring rule, apply it blind, and state it with the result.
5. Include an arrested control. A serum starved or confluent population gives the low end of the scale and shows the stain is reporting biology rather than background. It costs one well and settles most disputes about a threshold.

Persistence is what misleads

Several widely used proliferation markers remain detectable for a period after a cell leaves the cycle. In a tissue where cells are entering and leaving continuously, that lag inflates the apparent fraction and does so differently in different tissues.

Where the comparison matters, pair the marker with a phase specific reagent or with an incorporation experiment. The two together bound the answer in a way neither does alone.

Scoring is where the variance lives

Two people scoring the same section can differ substantially, and automated scoring differs again depending on threshold and segmentation. This variability usually exceeds the biological effect being measured.

Write the scoring rule down, validate it on a set both scorers assess, and keep the images. It converts an argument about impressions into a number with a method attached.

A cyclin h antibody and the kinase partner it is read with

Cyclin H pairs with CDK7 in the activating kinase and in the transcription machinery, so a cyclin h antibody reports a complex component whose level barely moves through the cycle. That makes it a poor proliferation marker and a useful loading and pulldown reagent. Where the question is activity, the readout is phosphorylation of a CDK activation loop or of the polymerase tail rather than the cyclin itself.

A cyclin b antibody and the window it is present in

Cyclin B accumulates through S and G2 and is destroyed at anaphase, so a cyclin b antibody reports position in the cycle by a band that comes and goes, and an asynchronous population averages that away. Synchronisation and a stated harvest time are therefore part of the method. Nuclear translocation before mitosis means the location carries information the blot cannot.

A top2a antibody as a proliferation marker beside Ki-67

Topoisomerase 2 alpha is expressed in cycling cells and is read in pathology as a proliferation marker, so a top2a antibody answers the same question as the page's own antigen from a different angle and the two are often scored together. The alpha and beta forms differ in expression pattern, so the clone has to name which, and a cycling positive control on the same slide is the internal check.

A cdk1 antibody and the phosphorylation that gates mitosis

CDK1 protein is present throughout the cycle while its activity is gated by inhibitory phosphorylation and by cyclin binding, so a cdk1 antibody for total protein measures very little on its own. The informative reagents are a phospho clone against the inhibitory tyrosine and a cyclin blot beside it. A mitotic arrest with a stated drug and duration is the positive control the figure needs.

An mcm2 antibody and licensing rather than division

The replication licensing factors are loaded before S phase and mark cells that are competent to divide, which is not the same set as cells that are dividing. An mcm2 antibody therefore reads higher than a mitotic marker in the same tissue, and that difference is the point when proliferative reserve is the question. It is chromatin bound, so extraction has to reach it.

Common questions

Does a proliferation index measure growth rate?

No. It measures the fraction of cells in cycle at one moment. A population with a long cycle can show a high index and divide slowly, which is why comparing indices between very different cell types is unsafe.

Why do two proliferation markers, such as a Ki67 antibody and a p16 antibody, disagree?

Because they mark different things: one may persist after the cycle stops, another may be degraded rapidly at a specific phase. Disagreement is usually informative rather than an error.

When is nucleotide incorporation the better choice?

When the question is how many cells divided during a defined window, rather than how many were in cycle when the sample was taken. It requires the label, the exposure window and a denaturation step the marker stains do not.

Browse by service class

• Compare Gene synthesis on advertised prices